Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.

Biotechnology

Research

Roquefort Therapeutics

Roquefort Therapeutics' headquarters in London, United Kingdom

Dr Darrin M Disley Obe

Martin Evans

Graham Robertson

Stephen West

Simon Sinclair

Michael Stein

Trevor M. Jones

Darrin Disley

Jean Duvall

Roquefort Therapeutics

Org chart

Board & advisors

Teams

Offices

Roquefort Therapeutics

Org chart

Board & advisors

Teams

Offices

Related companies